According to Helix Biopharma latest financial reports the cash on hand of HBP is $560.45K, an decrease of -75.15% to 2022. At the end of 2022 company had $2.26M cash on hand. This amount reflects the liquid assets available to the company, which are crucial for its operational flexibility, investment opportunities, and overall financial security.
Year | Cash on Hand | Change |
---|---|---|
2023 | $560.45K | -75.15% |
2022 | $2.26M | -8.78% |
2021 | $2.47M | -15.82% |
2020 | $2.94M | 1955.83% |
2019 | $142.89K | - |